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SUMMARY STATEMENT 
 
We present crystal structures of a trimeric coiled-coil domain found in EML proteins. This 
trimerization domain mediates self-association and interactions between a subset of EML proteins. 
Microtubule-association of EML proteins requires the trimerization domain and an adjacent basic 
region. 
 
 
ABSTRACT 
 
Proteins of the echinoderm microtubule associated protein-like (EML) family contribute to formation 
of the mitotic spindle and interphase microtubule (MT) network. EML1-4 consist of WD40 repeats 
and an N-terminal region containing a putative coiled-coil. Recurrent gene rearrangements in non-
small cell lung cancer (NSCLC) fuse EML4 to anaplastic lymphoma kinase (ALK) causing 
expression of several oncogenic fusion variants. The fusions have constitutive ALK activity due to 
self-association through the EML4 coiled-coil. We have determined crystal structures of the coiled-
coils from EML2 and EML4, which describe the structural basis of both EML self-association and 
oncogenic EML4-ALK activation. The structures reveal a trimeric oligomerization state directed by 
a conserved pattern of hydrophobic residues and salt bridges. We show that the trimerization 
domain (TD) of EML1 is necessary and sufficient for self-association. The TD is also essential for 
MT binding, however this property requires an adjacent basic region. These observations 
prompted us to investigate MT association of EML4-ALK and EML1-ABL1 fusions in which variable 
portions of the EML component are present. Uniquely, EML4-ALK variant 3, which includes the TD 
and basic region of EML4 but none of the WD40 repeats, was localized to MTs, both when 
expressed recombinantly and in a patient-derived NSCLC cell line (H2228). This raises the 
question of whether the mislocalization of ALK activity to MTs might influence downstream 
signalling and malignant properties of cells. Furthermore, the structure of EML4 TD may enable the 
development of protein-protein interaction inhibitors targeting the trimerization interface, providing 
a possible avenue towards therapeutic intervention in EML4-ALK NSCLC. 
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INTRODUCTION 
 
Microtubules (MTs) are polymers of tubulin heterodimers that form a dynamic network as 
part of the eukaryotic cytoskeleton. They carry out many essential cellular processes including 
forming an intracellular transport system for RNAs, proteins and organelles and regulating cell 
motility and changes in cell shape [1, 2]. In mitosis, MTs form the spindle apparatus that 
segregates chromosomes into two equal sets. The dynamic nature of MTs - their stochastic growth 
and shrinkage - is crucial for their function and is regulated by MT-associated proteins (MAPs) [3]. 
 The present work is focused on the echinoderm MT-associated protein (EMAP)-like (EML) 
family of MAPs. The archetypal member of this family was identified as the most abundant MAP in 
dividing echinoderm eggs and embryos [4]. Further members of the EML family associate with 
MTs and are essential for the proper formation of both the interphase MT network and the mitotic 
spindle [5-8]. EML proteins affect microtubule dynamics, and may act as scaffold proteins to 
localize mitotic kinases to MTs [5, 9, 10]. Drosophila and C. elegans each have a single EML 
homologue, whereas six EML proteins are present in humans of which EML1-4 have molecular 
weights in the 70-120 kDa range while EML5 and 6 are in excess of 200 kDa. The EML proteins 
contain WD40 repeats, and in EML1-4 these fall within a ~70 kDa core region that begins with a 
conserved ~60 amino acid sequence that has been termed the ‘hydrophobic EML protein’ (HELP) 
motif [5]. We recently determined the crystal structure of the core HELP/WD region of human 
EML1, which forms a tandem atypical β-propeller (TAPE) domain that binds soluble tubulin! [11].  
Most splice variants of EML1-4 are also predicted to contain a coiled-coil in the N-terminal region.  
 Rearrangements in the short arm of chromosome 2 leading to genetic fusions between 
EML4 and the gene encoding anaplastic lymphoma kinase (ALK) occur in ~5% of cases of non-
small cell lung cancer (NSCLC) [12]. Multiple variants of the EML4-ALK fusion have been identified 
in NSCLC resulting from translocations at different points within the EML4 gene [13]. A similar 
genetic fusion has also been reported between EML1 and the gene encoding another tyrosine 
kinase Abelson 1 (ABL1) in T-cell acute lymphoblastic leukaemia [14]. These fusions have potent 
transforming activity due to constitutive activation of the tyrosine kinase but confer addiction to the 
oncogene and inhibition of the tyrosine kinase induces apoptosis in transformed cells [15, 16]. 
Transforming activity of EML4-ALK variant 1 is dependent on the N-terminal region, and this is 
proposed to be due to oligomerization of ALK [12]. Indeed, this hypothesis appears to be 
confirmed by the identification of EML4-ALK variant 5, which encodes just the N-terminal region up 
to the end of the predicted coiled-coil [17]. 
In this study we determined the crystal structure of the N-terminal region of EML proteins 
that is required to drive the transforming capability of EML4-ALK fusions and reveal a trimeric state 
of oligomerization. We then investigated the role of this coiled-coil in MT binding in both EML 
proteins and oncogenic EML-kinase fusions. 
 
 
MATERIALS AND METHODS 
 
Gene manipulation 
 Human EML cDNAs were cloned by PCR from human cDNA (Clontech). Products 
encoding EML4 6-64 and EML2 isoform 2 11-60 were amplified by PCR and cloned into a modified 
version of pET30. Constructs were made comprising EML1 residues 167-815 (TAPE domain), 1-
174 (N-terminus), 23-78 (TD) and 80-815 (Δ-TD). The EML1 AAAA mutant contained the 
mutations L59A and D61A. Cloning of EML1-ABL1 and EML4-ALK variants was described 
previously [11]. Site-directed mutagenesis was carried out by the Quikchange procedure 
(Stratagene). 
 
Protein expression and purification 
His-tagged EML2 11-60 and EML4 6-64 I38M were expressed in B834 cells grown in Luria 
broth and SelenoMet Medium (Molecular Dimensions) respectively. The proteins were purified 
from clarified lysate in 50 mM HEPES pH 7.5, 500 mM NaCl using a nickel-charged 5 mL 
Chelating Sepharose column and eluted on a gradient from 50-500 mM imidazole. His-tags were 
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removed by digestion with tobacco etch virus (TEV) protease and the protein passed through a 
second Chelating Sepharose column. Finally, the proteins were gel filtrated into 10 mM Hepes pH 
7.5, 80 mM NaCl, 2 mM dithiothreitol (DTT) on a Superdex 75 16/60 column (GE Healthcare). 
 
Crystal structure determination 
Crystals of EML4 6-64 I38M and EML2 11-60 were obtained by the hanging drop vapour 
diffusion method using 100 mM Tris/HCl pH 8.5, 30% PEG 4000, 200 mM MgCl2 and 100 mM Bis-
Tris-propane pH 6.5, 20% PEG 3350, 200 mM potassium thiocyanate respectively in the reservoir 
and were flash frozen in the same solutions with the addition of 20% glycerol and 5 mM DTT. 
Drops were formed from ~15 mg/mL protein solution mixed 1:1 with reservoir solution and 
incubated at 18°C for ~2 days. 
Single-wavelength anomalous dispersion data to a resolution of 2.9 Å was collected from 
an EML4 6-64 I38M selenomethionine derivative crystal at Diamond I02. Diffraction images were 
indexed using imosflm [18] and scaled using scala! [19]. An initial map and model were obtained 
using PHENIX to locate selenium sites [20] revealing one trimer in the asymmetric unit. Manual 
rebuilding was carried out using COOT [21]. The 2.1 Å data was collected from a native EML2 11-
60 crystal at Diamond I04. PHENIX was used to solve the structure of EML2 11-60 by molecular 
replacement phasing with the EML4 6-64 I38M structure, to automatically build the two trimers in 
the asymmetric unit, and for refinement. 
 
In vitro MT-binding assays 
Tubulin was prepared from pig brain as described previously [22]. Labeled tubulin was from 
Cytoskeleton Inc. YFP-EML1 proteins for use in in vitro microtubule binding assays were 
expressed as FLAG-Strep2 fusions in HEK293F suspension culture and purified from clarified cell 
lysate on Strep-tactin Sepharose (Qiagen) in Tris-buffered saline (TBS) and eluted using 3 mM 
desthiobiotin (IBA), followed by incubation with GST-tagged 3C protease to cleave off the tag and 
then passed over a Glutathione-sepharose column to remove the protease. Finally, the protein was 
separated from co-purifying tubulin by gel filtration on a Superose 6 column (GE Healthcare) in 20 
mM Tris/HCl pH 7.5, 80 mM NaCl, 2 mM DTT before dialysis into MRB80 (80 mM PIPES, pH 6.8 
with KOH, 1 mM EGTA, 4 mM MgCl2) + 50 mM KCl and concentration to 20 µM. MT seeds were 
assembled from tubulin, biotin-tubulin and Hilyte647-tubulin at a molar ratio of 25:1:2 in the 
presence of 1 mM GMP-CPP in MRB80 for 1 hr at 37ºC, diluted 20-fold with MRB80 + 2 µM Taxol 
and stored at 21°C. A 100 µm deep flow chamber was made from a slide and a HCl-treated 
coverslip using double-sided Scotch tape (3M) and passivated with PLL-PEG-50% biotin (Susos 
AG). Seeds were attached to this surface using streptavidin and blocked with 1 mg/mL κ-casein 
(Sigma). A reaction mix containing 12 µM tubulin, 1 µM rhodamine-tubulin, 50 mM KCl, 1 mM 
GTP, 0.6 mg/ml κ-casein, 0.2% methyl cellulose, 4 mM DTT, 0.2 mg/mL catalase, 0.4 mg/mL 
glucose oxidase, 50 mM glucose in MRB80, supplemented with 500 nM YFP-EML1 protein or 
buffer was clarified for 8 min at 190,000xg in an airfuge (Beckman), the supernatant added to the 
flow chamber and sealed with candle wax. For MT-binding experiments in the absence of free 
tubulin the reaction mix was prepared as above but lacking tubulin and assays carried out using 
GMP-CPP stabilized MTs.  
MTs were observed on an Olympus TIRF system with a 100x NA 1.49 objective, 488 nm, 
561 nm and 640 nm laser lines and a Hamamatsu ImageEM-1k back-illuminated EM-CCD camera 
under the control of xcellence software. To quantify MT-bound YFP-EML1 proteins the average 
YFP-fluorescence intensity along a 3 pixel wide line along the MT was measured using ImageJ. 
 
Cell culture and transfection 
HeLa, HEK293 and U2OS cells were grown in Dulbecco’s modified Eagle’s medium 
(Gibco) supplemented with 10% heat-inactivated foetal bovine serum (FBS), 100 IU/mL penicillin 
and 100 µg/mL streptomycin at 37°C in a 5% CO2 atmosphere. EML constructs, EML1-ABL1 and 
EML4-ALK variants were cloned into pcDNA3 or pcDNA3.1-hygro (Invitrogen) with N-terminal 
YFP- or FLAG-tags. HeLa and HEK293 cells were transiently transfected with these plasmids 
using Fugene HD reagent (Promega) and U2OS cells using Lipofectamine 2000 (Invitrogen). 
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HEK293F cells were grown in suspension culture in Freestyle 293 medium (Gibco) in a 5% 
CO2 atmosphere and transfected with Strep2-YFP-EML1 constructs in a modified version of pMAX 
(Lonza) at a density of 1x106 cells/mL using 2 µg/mL polyethylenimine. 
 NCI-H2228 cells were provided by Dr S Gray (Institute of Molecular Medicine, St James's 
Hospital, Dublin, Ireland); NCI-H3122 cells were obtained from the NCI Tumor Repository 
(Frederick, MD, USA). Cells were cultured in RPMI medium 1640, 2mM Glutamax and 10% Foetal 
Calf Serum (Gibco). 
 
Fixed and live cell IF microscopy 
 For fixed cell microscopy, HeLa, H2228 and H3122 cells grown on acid-etched coverslips 
were fixed with ice cold methanol and processed for IF microscopy as described previously [23], 
with the modification that cells were blocked for 30 min in 1x PBS supplemented with 1% bovine 
serum albumin and 0.2% Triton X-100. Primary antibodies used were 1 µg/mL anti-GFP ab6556 
(Abcam), 0.3 µg/mL anti-α-tubulin (Sigma) and 1:200 anti-ALK D5F3 (Cell Signalling). Secondary 
antibodies were 1 µg/mL Alexa Fluor 488 conjugated goat anti-rabbit and Alexa Fluor 594 
conjugated goat anti-mouse IgGs (Invitrogen). Cells were imaged using a Leica SP5 laser 
scanning confocal microscope. Deconvolution of image stacks was carried out using Huygens 
Essential software and the z-stacks were assembled in ImageJ. Quantitative image analysis 
performed with LAS-AF software (Leica) or ImageJ. 
 
Western blot analysis 
 Primary antibodies for western blotting were mouse anti-FLAG M2 (Sigma) and rabbit anti-
GFP ab6556 (Abcam). Secondary antibodies were horseradish peroxidase conjugated anti-mouse 
or anti-rabbit IgGs (GE Healthcare).  
 
 
RESULTS 
 
A conserved region in the EML N-terminus forms a trimerization domain 
 
 Proteins of the EML family contain regions N-terminal to the conserved TAPE core that are 
poorly conserved, often subject to splice variation and predicted to be mostly disordered. However, 
there is an island of conserved primary sequence within this region that is consistent with a coiled-
coil (Figure 1A). To investigate the structural basis of self-association we crystallized protein 
fragments corresponding to this part of human EML2 and EML4 proteins. The structure was 
determined by single-wavelength anomalous dispersion phasing using crystals of a 
selenomethionine-labelled EML4 6-64 I38M mutant (Table 1, Figure 1B, Supplementary Figure 
S1A). Only residues 14-44 were visible in the electron density map but most strikingly they formed 
a trimeric coiled-coil. We then obtained 2.1 Å diffraction data using crystals of EML2 isoform 2 
residues 11-60 and solved its structure by molecular replacement phasing (Table 1, Figure 1C, 
Supplementary Figure S1B). 
The EML trimerization domain (TD) forms an amphipathic α-helix with a series of nine 
conserved hydrophobic residues (predominantly leucine and valine) along the inner face whose 
side chains pack together into the core of the trimer (coloured yellow in Figure 1). A conserved 
glutamine (Gln29 in EML2, coloured grey in Figure 1D) on the inner face makes hydrogen bond 
interactions with main-chain carbonyls in the core, perhaps serving to maintain the register of the 
coiled-coil. Interspersed between the hydrophobic residues in the sequence are conserved 
charged residues whose side chains are positioned to form salt-bridges with those of the adjacent 
protomers around the outside of the trimer (coloured light blue in Figure 1). The pattern of 
conserved residues indicates that human EML1-4 are all trimeric, as are their respective oncogenic 
fusion proteins (Figure 1E).  
 
The trimerization domain is critical for EML self-association  
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 The most conserved surface patch in the TD is composed of several amino acids with short 
side chains (ALAD motif), which constrict the shape of the coiled-coil (Figure 2A). We investigated 
whether the TD or disruption of the ALAD motif affect self-association in a representative member 
of the EML family, EML1. We tested the ability of various YFP-tagged EML1 constructs to co-
immunoprecipitate with FLAG-tagged full-length EML1 from lysates of co-transfected HEK293 cells 
(Figure 2B). Full-length EML1 (FL), the isolated N-terminus (1-174) and a construct corresponding 
to residues 23-78 (trimerization domain; TD) co-immunoprecipitated with full-length EML1 while the 
TAPE region did not. A double mutation (L59A, D61A) in the most conserved motif in the TD 
(AAAA) did not disrupt self-association but deletion of the whole conserved region (Δ-TD) 
abrogated self-association completely. 
 The key residues involved in self-association within the trimerization domain are imperfectly 
conserved, and EML3 has the most divergent TD (Figure 1E). This observation prompted us to 
investigate whether EML3 could self-associate, and whether associations between EML3 and 
other members of the EML family could happen. We tested the ability of YFP-EML3 to co-
immunoprecipitate with FLAG-EML1, FLAG-EML2 or FLAG-EML3 from lysates of co-transfected 
HEK293 cells (Figure 2C). YFP-EML3 co-immunoprecipitated with FLAG-EML3 and, more weakly, 
with FLAG-EML2, but not with YFP-EML1. This is consistent with the degree of conservation within 
the 17 key residues involved in self-association: EML1 and EML2 - 12 identical, 5 conservatively 
substituted; EML1 and EML3 - 6 identical, 5 conservatively substituted, 5 non-conserved; EML2 
and EML3 - 9 identical, 3 conservatively substituted, 5 non-conserved. 
 
The trimerization domain is critical for MT binding 
 
 We confirmed co-localization of YFP-tagged human EML1 to the interphase MT network of 
transiently transfected HeLa cells, as has been previously observed for endogenous EML proteins 
(Figure 3) [5-8]. Overexpression of a tagged protein might affect its regulation and distribution on 
microtubules, and we shall not comment on these features of the data. However, this approach 
enabled us to screen the MT-binding properties of multiple YFP-EML1 constructs to identify which 
domains were needed for this activity (Figure 3A). The co-localization of YFP-EML1 proteins with 
MTs was visualised (Figure 3B) and quantified (Figure 3C).  
The isolated N-terminal region (aa 1-174), which is not conserved at the sequence level for 
most of its length but includes the TD, strongly associated with MTs. However, neither the 
putatively disordered region lying between the TD and TAPE domains (74-174) nor the TD alone 
(23-78), nor the isolated TAPE domain were sufficient to associate with MTs in cells. Deletion of 
the TD from EML1 considerably reduced its interaction with MTs in cells, whereas mutation of the 
ALAD motif within the TD decreased MT co-localization modestly. The overexpressed EML1 
proteins might interact directly with MTs, through association with endogenous EML1 or other 
EMLs, or indeed through associations with other MAPs. To distinguish between these different 
modes of interaction, direct binding of recombinantly expressed and purified YFP-EML1 protein 
constructs to purified MTs was measured in vitro by total internal reflection fluorescence (TIRF) 
microscopy (Figure 4). Here, direct association of full-length EML1 and the N-terminal region with 
MTs was measured, whereas the isolated TAPE domain did not associate (Figure 4A,C); full-
length EML1 with a mutated ALAD motif exhibited reduced binding compared to wild-type, and the 
deletion of the TD abolished MT interaction altogether (Figure 4B,D). 
 
Taken together, the results from the cell-based and in vitro MT-binding assays demonstrate 
that the N-terminal region of EML1 confers MT binding and that the TD is required. However, the 
TD is not sufficient for MT association, which requires other sequences in the N-terminal region.  
  
 
EML4-ALK variant 3 localizes to MTs  
  
Having identified the N-terminus as a MT-binding region of EML proteins, and recognising 
that it is intact in many of the fusion oncoproteins, we supposed that the fusion oncoproteins might 
be targeted to MTs. We examined HeLa cells transfected with YFP-tagged EML-tyrosine kinase 
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fusions (Figure 5A-C) and found that this was not generally the case: EML4-ALK variants 1 and 2 
and EML1-ABL1 form cytoplasmic aggregates and EML4-ALK variant 5a is diffusely localized in 
the cytoplasm, while only EML4-ALK variant 3a was localized to MTs.  Next we investigated by 
immunofluorescence microscopy the localization of the endogenous EML4-ALK fusion proteins in 
two patient-derived NSCLC cell lines, H3122 and H2228 (Figure 5D-F). The variant 1 protein 
present in H3122 cells displayed a patchy appearance in the cytoplasm consistent with a protein 
that is largely aggregated but the variant 3b protein in H2228 cells was localized to the MT 
network.  
 Taken together, these results show that the N-terminal domain of EML4 is able to confer 
MT localization on EML4-ALK variant 3, but not when a truncated part of the EML4 TAPE domain 
is present as in variants 1 and 2. 
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DISCUSSION 
 
Association of the EML1 N-terminal region with MTs requires both the TD and the ~90 
residue region between the TD and TAPE domains. This latter, putatively disordered, inter-domain 
region is not conserved at the sequence level but contains many basic residues. The TD 
presumably enhances binding of EML proteins to MTs through an avidity effect, and may 
contribute directly to the interaction through a conserved surface region that is disrupted by the 
AAAA mutation.  
EML oncogenic fusions such as EML4-ALK and EML1-ABL1 are naturally occurring and 
exist in a context in which the MT binding properties of the EML N-terminus are isolated from the 
TAPE region. In EML4-ALK variant 3a/b the whole of the EML4 N-terminal region, and evidently its 
MT-binding activity, is transferred to the fusion protein (Figure 6). EML4-ALK variant 5 has a TD, 
but lacks the basic region, and is therefore incapable of binding to MTs. The other EML4-ALK 
variants and EML1-ABL1 contain a complete N-terminus encompassing the TD and basic region, 
and might be expected to localize to MTs, but do not. In these cases, it appears that the presence 
of a partial TAPE domain interferes with MT binding, perhaps through protein misfolding leading to 
aggregation into complexes with Hsp90 that may sterically block MT association. Indeed, the 
microscopy studies of several of the EML-kinase fusions, including endogenous EML4-ALK variant 
1 in H3122 cells, were consistent with aggregation of these proteins. Furthermore, we have 
previously shown that EML4-ALK variants 1 and 2 are more sensitive to Hsp90 inhibitors than 
variants 3 and 5 [11].   
 The EML2 and EML4 TD structures presented here reveal that EML proteins and EML4-
ALK oncoproteins self-associate as trimers through a specific and stable coiled-coil interface. The 
more widely expressed isoform 1 of EML2 does not possess a TD region and is therefore unlikely 
to interact directly with other EMLs but a TD is present in the brain/spinal cord variant isoform 2 
studied here![24]. EML3 can also self-associate, and can interact with EML2 isoform 2, but not with 
EML1. The functional relevance of interactions between EML family members is not clear, but the 
potential for these interactions should be borne in mind during functional studies.  
 
 It is notable that the more divergent human paralogues, EML5 and EML6, lack coiled-coil regions 
but have three copies of the TAPE region each. Thus, the quaternary structure of all six human 
EML proteins may feature three TAPE regions (Figure 6A). In oncogenic ALK-fusions 
oligomerization conferred by the fusion partner mimics the native oligomerization-dependent 
activation mechanism of receptor tyrosine kinases and engenders constitutive activation of ALK 
[25]. The use of rationally-designed peptide and peptidomimetic inhibitors is under investigation for 
the disruption of several coiled-coil interactions that are implicated in disease and clinically useful 
therapeutics have been developed using this approach [27, 28, 29]. The TD structures may enable 
the development of protein-protein interaction inhibitors targeting the trimerization interface of the 
EML4 TD, another possible avenue towards therapeutic intervention in EML4-ALK NSCLC and 
one that would be applicable to all variants. 
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Figure Legends 
Figure 1  The N-termini of EML proteins contain a trimerization domain (TD).  (A) Schematic 
diagram of domain organization in EML1.  (B) A view along the threefold axis of the EML4 TD.  In 
B-D, side chains forming the hydrophobic core of the trimer are shown in yellow and those forming 
salt-bridges are shown in light blue. (C) A view along the threefold axis of the EML2 TD. (D) The 
structure of the EML2 TD shown as a cartoon representation (pink) with key residues in two of the 
protomers shown as stick representations. Gln29 is shown in grey. Below, the arrows linking the 
pair of sequences indicate salt-bridge pairing in adjacent protomers.  (E) A sequence alignment of 
the TD region of human EML proteins. Residues are coloured as in B-D and boxes indicate the 
regions present in the EML2 and EML4 TD structures. Conservation is shown underneath - 
identical residues and highly conserved residues are marked by (*) and (:) respectively. Gln29 and 
the ALAD motif are underlined.  
 
Figure 2  Oligomerization of EML1 depends on the TD.  (A) Sequence conservation mapped 
onto the surface of the EML2 TD structure; residues that are identical among human EML proteins 
are coloured red and highly conserved residues are coloured orange.  (B) Immunoblot analysis of 
EML1 self-association. HEK293 cells were co-transfected with FLAG-EML1 and various YFP-
EML1 constructs as indicated (top two panels). Proteins were immunoprecipitated using anti-FLAG 
M2 (Sigma) (lower two panels). Cell extracts were prepared as previously described [26] and 
analysed by SDS-PAGE and western blotting using anti-FLAG M2 and anti-GFP antibodies. (C) 
EML3 association with EML1-3. U2OS cells were co-transfected with YFP-EML3 and FLAG-EML1-
3 as indicated. Immunoprecipitation and analysis was carried out as in (B). 
 
Figure 3  Microtubule association of EML1  (A) Schematic illustrations of EML1 constructs.  (B) 
Immunofluorescence microscopy images of interphase HeLa cells transfected with YFP-tagged 
EML1 constructs (z-projections; lower image) and of a magnified single MT (one focal plane; upper 
image). Cells are stained with Hoechst 33258 (blue, DNA) and anti-GFP (green) and anti-α-tubulin 
(red, MTs) antibodies. Scale bar, 10 µm.  (C) Representative intensity profiles along a line crossing 
2-3 MTs showing co-localization of YFP-fusions with MTs. R (Pearson’s correlation coefficient) 
measures the correlation between the YFP and α-tubulin signals and is given as the mean of 
single line-scan measurements in 10 different cells for each construct +/- standard deviation (SD).  
 
Figure 4 Association of EML1 with microtubules assembled from purified tubulin  (A) 
Representative TIRF microscopy fields of view showing Hilyte640-labelled GMPCPP-stabilised MT 
seeds (left), XRhodamine-labelled dynamic MTs extensions (centre) and the binding to those MTs 
of 500 nM YFP-EML1 proteins as indicated in the presence of 12 µM free tubulin (right). Note even 
decoration with no preference for nucleotide state of tubulin. (B) TIRF images of Hilyte640-labelled 
GMPCPP-stabilised MTs (left) and their decoration by 500 nM YFP-tagged EML1 mutants in the 
absence of free tubulin (right). Scale bars 10µm. (C) Statistical box plots describing quantification 
of MT-binding of YFP-EML1 proteins in vitro by TIRF microscopy in the presence of 500 nM YFP-
tagged EML1 domains and 12 µM free tubulin. n=25-38 MTs. (D) Statistical box plots describing 
quantification of MT-binding of 500 nM YFP-tagged EML1 mutants without free tubulin. n= 30-201 
microtubules. Boxes in C and D show 25th, 50th and 75th percentile, whiskers show 10th and 90th 
percentile of data.  
 
Figure 5  Localization of EML4-ALK and EML1-ABL1 fusion proteins. (A) Schematic 
illustrations of EML-tyrosine kinase fusion constructs. (B) Immunofluorescence microscopy images 
of interphase HeLa cells transfected with YFP-tagged EML-tyrosine kinase fusion constructs as 
indicated, (lower image) and of a magnified single MT (upper image). Scale bar, 10 µm. (C) Co-
localization of each YFP-fusion with MTs was quantified as for Figure 3C. (D) Schematic 
illustrations of EML-tyrosine kinase fusion constructs in H3122 and H2228. (E) 
Immunofluorescence microscopy images of interphase NSCLC cells (lower image) and of a 
! 12!
magnified single MT (upper image). Scale bar, 10 µm. (F) Co-localization of ALK with MTs was 
quantified as for Figure 3C. 
 
Figure 6  Models summarising the properties of EML proteins and EML4-ALK variants.  (A) 
Cartoon illustrating trimerization and MT-binding in EML proteins.  (B) Cartoon illustrating 
trimerization and MT binding in EML4-ALK variant 3.  The constituent β-propellers of the EML 
TAPE domain are shown in teal and green and the Blade 12-N subdomain is shown in orange [11]. 
 
 
Supplementary Figure S1  Stereo images showing representative electron density maps for 
EML trimerization domain X-ray crystal structures.  Wire mesh shows 2mFo-DFc map 
contoured at 1.0σ.  (A) The 2.9Å structure of the EML4 trimerization domain I38M showing inter-
protomer salt-bridges.  (B) The 2.1Å structure of the EML2 trimerization domain showing the 
hydrophobic core. 
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Table 1  Summary of crystallographic analysis 
!
! EML4!TD!I38M! EML2!TD!! ! !
Lattice(parameters( ! ! !
Space!group! P43!21!2! P21!21!21!
!!!!a#(Å)  !
####b!(Å)  !!
####c#(Å)  
67.49!
67.49!
50.60!
47.87!
51.14!
101.69!
    α (°) 
    β (°)  
    γ!(°)!!
90.00!!
90.00!!
90.00!
90.00!
90.00!
90.00!
!
Data(collection(
XMray!source!
Wavelength!(Å)!
Resolution!range!(Å)!
!
!
Diamond!I02!
0.9796!
67.49M2.90!!
(3.06M2.90)*!
!
!
Diamond!I04!
0.9795!
50.86M2.15!!
(2.32M2.15)!
No.!unique!reflections!
Completeness!(%)!
2864!(394)!
100.0!(100.0)!
14593!(1058)!
99.8!(99.9)!
Redundancy!
Rmerge!(%)!
Rpim#(%)!
I#/!σI#
!
Phasing((figures(of(merit)(
before!density!modification!
13.4!(14.4)!
13!(125)!
4.1!(33.2)!
13.3!(3.1)!
!
!
0.39!
7.0!(7.3)!
8.5!(63.8)!
3.8!(27.2)!
14.2!(3.2)!
!!!!
!
!!!M!
after!density!modification!
!
Refinement!
0.74! !!!M!
Resolution!range!(Å)! 47.7M2.9! 50.9M2.2!
Rwork!/!Rfree!!(%)! 26.87!/!29.15! 20.78!/!25.15!
No.!protein!molecules!
No.!amino!acids(
3!
83!
6!
254!
No.!water!molecules! 0! 102!
No.!hetero!molecules! 0! 3!
Mean#BMfactors!(Å2)! ! !
!!!!protein! 88.75! 43.30!
!!!!water! !!!M! 46.05!
!!!!hetero! !!!M! 50.31!
r.m.s.!deviations! ! !
!!!!bond!lengths!(Å)! 0.006! 0.006!
!!!!bond!angles!(°)!
!
MolProbity(analysis(
AllMatom!clashMscore!
Poor!rotamers!(%)!
Ramachandran!outliers!(%)!
Ramachandran!favoured!(%)!
MolProbity!score!
!
!
1.02!
!
!
17.12!
8.8!
0.0!
100.0!
1.99!
0.930!
!
!
8.97!
5.1!
0.0!
99.6!
1.93!
 
*Values in parentheses are for the highest-resolution shell. 
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